Brokerages predict that EXACT Sciences Co. (NASDAQ:EXAS) will announce $103.93 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for EXACT Sciences’ earnings, with the lowest sales estimate coming in at $101.66 million and the highest estimate coming in at $105.51 million. EXACT Sciences reported sales of $57.65 million during the same quarter last year, which indicates a positive year over year growth rate of 80.3%. The firm is expected to report its next earnings report on Tuesday, July 24th.
On average, analysts expect that EXACT Sciences will report full-year sales of $430.94 million for the current fiscal year, with estimates ranging from $429.20 million to $432.20 million. For the next year, analysts expect that the business will report sales of $640.83 million per share, with estimates ranging from $624.15 million to $658.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that cover EXACT Sciences.
EXACT Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Thursday, April 26th. The medical research company reported ($0.33) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.05. The company had revenue of $90.30 million for the quarter, compared to analyst estimates of $86.31 million. EXACT Sciences had a negative return on equity of 20.92% and a negative net margin of 38.61%. The firm’s quarterly revenue was up 86.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.32) earnings per share.
EXACT Sciences stock opened at $51.35 on Thursday. The company has a current ratio of 15.30, a quick ratio of 14.86 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $6.37 billion, a P/E ratio of -51.87 and a beta of 0.86. EXACT Sciences has a one year low of $31.04 and a one year high of $63.60.
In other news, SVP D Scott Coward sold 4,420 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $42.34, for a total transaction of $187,142.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Kevin T. Conroy sold 25,319 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $42.34, for a total value of $1,072,006.46. Following the sale, the insider now owns 211,183 shares of the company’s stock, valued at approximately $8,941,488.22. The disclosure for this sale can be found here. Over the last three months, insiders sold 135,748 shares of company stock worth $6,082,759. Insiders own 4.00% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cornerstone Capital Management Holdings LLC. increased its holdings in shares of EXACT Sciences by 5.0% during the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 44,361 shares of the medical research company’s stock valued at $2,330,000 after acquiring an additional 2,100 shares in the last quarter. Teachers Advisors LLC increased its holdings in shares of EXACT Sciences by 1.1% during the fourth quarter. Teachers Advisors LLC now owns 212,440 shares of the medical research company’s stock valued at $11,162,000 after acquiring an additional 2,294 shares in the last quarter. MetLife Investment Advisors LLC bought a new stake in shares of EXACT Sciences during the fourth quarter valued at approximately $2,855,000. Emerald Advisers Inc. PA bought a new stake in shares of EXACT Sciences during the fourth quarter valued at approximately $21,813,000. Finally, Swiss National Bank increased its holdings in shares of EXACT Sciences by 3.1% during the fourth quarter. Swiss National Bank now owns 202,819 shares of the medical research company’s stock valued at $10,656,000 after acquiring an additional 6,100 shares in the last quarter. Hedge funds and other institutional investors own 88.72% of the company’s stock.
EXACT Sciences Company Profile
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.